Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs - Fierce Biotech
Source: Fierce Biotech ·
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs Fierce BiotechVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal ReutersVir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors Business WireVir…